Medical Dialogues
  • Dermatology
Sign in Signup
This site is intended for healthcare professionals only
Sign in Signup
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
Medical Dialogues
  • Medical News
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Medical Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
  • MDTV
      • Anesthesia
      • CTVS
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • Diet and nutrition
      • ENT
      • Gastroenterology
      • Health Dialogues
      • Health News today
      • Health Shorts
      • Health Updates
      • Health video of the day
      • Laboratory Medicine
      • Latest Videos
      • Latest Webinars
      • MD shorts
      • Medical News Today
      • Medical Updates
      • Medical Video of the day
      • Medicine
      • Nephrology
      • Neurology and Neurosurgery
      • Obstetrics and Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics & Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Top Videos
      • Urology
This site is intended for healthcare professionals only
Sign InRegister
Medical Dialogues
Sign inRegister
  • Home
  • Medical news
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Medical Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
  • Case of the Day
  • Editorial
  • Home
  • ENT
  • ENT News
  • Subcutaneous...

Subcutaneous Mepolizumab treatment for chronic rhinosinusitis decreases nasal polyps and obstruction

Medical Dialogues Editorial TeamBy Medical Dialogues Editorial TeamPublished On 2022-02-03T09:00:09+05:30  |  Updated On 2022-02-03T09:00:27+05:30
Subcutaneous Mepolizumab treatment for chronic rhinosinusitis decreases nasal polyps and obstruction

A group of researchers led by Claus Bachert conducted a study which showed that regardless of the existence of asthma or aspirin-exacerbated respiratory illness (AERD), mepolizumab decreased polyp size and nasal obstruction in Chronic Rhinosinusitis with Nasal Polyp (CRSwNP). The findings of this study were published in the Journal of Allergy and Clinical Immunology.Mepolizumab decreased...

A group of researchers led by Claus Bachert conducted a study which showed that regardless of the existence of asthma or aspirin-exacerbated respiratory illness (AERD), mepolizumab decreased polyp size and nasal obstruction in Chronic Rhinosinusitis with Nasal Polyp (CRSwNP).

The findings of this study were published in the Journal of Allergy and Clinical Immunology.

Mepolizumab decreased nasal polyp (NP) size and nasal obstruction in CRSwNP in the Phase III SYNAPSE research. As a result, the goal of this study was to evaluate the effectiveness of mepolizumab in SYNAPSE patients classified by concomitant asthma, AERD, and baseline blood eosinophil count (BEC).

SYNAPSE, a 52-week randomized, double-blind trial (NCT03085797), comprised individuals with severe bilateral CRSwNP who were surgical candidates despite intranasal corticosteroid therapy. For 52 weeks, patients were given subcutaneous mepolizumab 100 mg four times a week or placebo, in addition to usual therapy. Changes in total endoscopic NP score (Week 52) and nasal obstruction visual analogue scale (VAS) score (Week 49–52) were co-primary objectives. The subgroup analyses by concomitant asthma and AERD status, as well as the post-hoc analysis by BEC, were exploratory.

The key findings of this study were as follow:

1. The study comprised 407 people (289 with asthma, 108 with AERD, and 371 and 278 with BEC counts of 150 or 300 cells/L, respectively).

2. The proportion of patients with a 1-point improvement from baseline in NP score was higher with mepolizumab versus placebo across comorbid diseases (asthma: 52.9% vs 29.5 % ; AERD: 51.1% vs 20.6%) and baseline BEC subgroups (150 cells/L: 55.0 percent vs 31.3 % ; 150 cells/L: 49.5% vs 28.1 % ; 300 cells/L: 50.7 %.

3. A similar pattern was found in patients who did not have concomitant asthma or AERD.

4. Across all comorbid categories, mepolizumab resulted in a more than 3-point improvement in nasal obstruction VAS score compared to placebo.

In conclusion, 100 mg subcutaneous mepolizumab administration every 4 weeks decreased NP size, nasal obstruction, surgical risk, and systemic corticosteroid usage, with a trend for larger improvement in individuals with higher baseline blood eosinophil levels. The medication also alleviated nasal symptoms in individuals with severe, bilateral CRSwNP, whether they had asthma, AERD, or both. Mepolizumab should be investigated for the treatment of CRSwNP, especially in individuals who also have asthma or AERD.

Reference:

 Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, Maspero JF, Smith SG, Kante O, Karidi-Andrioti DE, Mayer B, Chan RH, Yancey SW, Chaker AM, Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count, Journal of Allergy and Clinical Immunology (2022), doi:https://doi.org/10.1016/j.jaci.2021.10.040


Journal of Allergy and Clinical Immunology mepolizumab chronic rhinosinusitis 
Source : Journal of Allergy and Clinical Immunology
Medical Dialogues Editorial Team
Medical Dialogues Editorial Team

    Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Air pollution and allergic rhinitis: Understanding the invisible, yet the inevitable  connection

    Air pollution and allergic rhinitis: Understanding the invisible, yet the inevitable connection

    Treatment challenges in managing Gastroparesis related to PPI Use: Analyzing scope of Probiotics

    Treatment challenges in managing Gastroparesis related to PPI Use: Analyzing scope of Probiotics

    Review: Efficacy of Antiviral Agents Against  Omicron Subvariant BA.2

    Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    View All

    Journal Club Today

    Predicting Poor Neurocognitive Outcomes in Acute Carbon Monoxide Poisoning

    Predicting Poor Neurocognitive Outcomes in Acute Carbon Monoxide Poisoning

    View All

    Health News Today

    Health Bulletin 20/May/2022

    Health Bulletin 20/May/2022

    View All
    © 2019 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X